A Fortune Most Powerful Woman, Posnett is global co-head of investment banking and a member of the Management Committee.

"Aktis Oncology kicks 2026 IPO cycle off with $210m target" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.

A logjam keeping companies worth as much as $2.9 trillion, from SpaceX to OpenAI, out of public stock markets may finally ...

These listings could set off a feeding frenzy among public market investors who have been waiting to get a piece of AI boom, ...

After a flurry of new-age companies led IPOs in 2025, leading brokerage firm, SBI Securities expects the strong momentum to continue in 2026 with market sentiments undergoing a shift ...

After euphoric listings and sharp corrections, can India’s IPO market recalibrate valuations, protect retail capital, and ...

The recent IPO boom signals confidence in India’s economic story, but confidence should not slide into complacency ...

Kraken’s pending IPO and the wave of crypto companies seeking public listings may help the industry attract more TradFi capital. A potential initial public offering (IPO) next year by cryptocurrency ...

Renaissance IPO ETF (IPO) is rated a buy, anticipating a surge in major IPOs through 2026 to fuel renewed investor interest.

Bitpanda is preparing to list its shares on the Frankfurt stock market as early as the first half of 2026, according to a ...